Granulopoiesis is regulated by multiple hematopoietic nulocyte colony-stimulating factor receptor (G-CSF-R) have growth factors. Granulocyte colony-stimulating factor (G-CSF) been described in three patients with severe congenital neutroplays a key role in the production of neutrophils. G-CSF pro- complexes that directly activate gene expression.
The underlying pathophysiological mechanisms of CN/SCN are largely unknown. G-CSF production by mononuclear cells Introduction from SCN patients appears to be normal, 19 and serum G-CSF levels are often increased. 20 These observations argue against Congenital neutropenia (CN) is a heterogeneous disease cona lack of G-CSF being the cause of neutropenia in these dition characterized by a selective paucity in circulating neupatients. An alternative hypothesis is that abnormalities in the trophils. The disease usually presents early in infancy, with a function of G-CSF-R could play a role in the pathogenesis of variable pattern of inheritance. [1] [2] [3] [4] Patients with CN experience CN/SCN. Support for this latter idea came from the discovery frequent episodes of bacterial infections, the risk and severity of a somatic mutation in the G-CSF-R gene in a patient with of which directly correlate with the absolute neutrophil count SCN. 21 This nonsense mutation resulted in the deletion of the of the blood. Severe congenital neutropenia (SCN), also C-terminal region of G-CSF-R that contains a domain essential known as Kostmann's syndrome or congenital agranulofor maturation signaling. 22, 23 Upon its ectopic expression in cytosis, is a form of CN with an absolute neutrophil count of murine myeloid cell lines L-GM or 32Dc10, the mutant recepless than 0.2 × 10 9 /l. Maturation arrest of myeloid progenitor tor protein failed to induce neutrophilic maturation. 22, 24 The cells in the bone marrow at the promyelocyte/myeloid stage mutation was found in the granulocytes of the patient (who is a characteristic feature of SCN.
1 A major concern is that CN received G-CSF treatment), but not in monocytes, erythroid patients have an increased probability of developing a myelocolony cells, T and B lymphocytes, and skin fibroblasts. This dysplastic syndrome or acute myeloblastic leukemia (AML). [5] [6] [7] [8] [9] suggested that the affected cells represented a clonal expanCurrently, the estimated frequency of transformation to MDS sion of granulocytic progenitor cells harboring the mutation, and AML in CN and SCN patients is approximately 7.5%. 9 phenomena reminiscent of a pre-leukemic condition. Mutations leading to the truncation of the G-CSF-R C-terminus at almost the same position were identified in two other Correspondence: IP Touw, Institute of Hematology, Erasmus Univerpatients, both of whom developed AML. 24 sity, PO Box 1738, 3000 DR Rotterdam, The Netherlands Received 5 July 1996; accepted 8 October 1996
In this paper, we present the results of a search for G-CSF-R mutations in 20 additional cases of CN and SCN. This series guanidinium isothiocyanate extraction and salting-out procedures, respectively. 26,27 RNA was converted into cDNA comprises three Swedish patients from the original pedigree of Kostmann (who first described SCN as an autosomal recessive using oligo(dT) primers and Moloney murine leukemia virusderived reverse transcriptase (RT; Gibco-BRL, Breda, The disorder 1 ) and two cases with disease progression to AML. Netherlands). PCR amplification on cDNA and genomic DNA was carried out as previously reported, 24 except that the annealing temperature was 54°C for all primer sets. The nucleMaterials and methods otide sequences of the PCR primers are given in Table 2 . RT-PCR was done with primers FW2 and RV2. This reaction genPatients erates a cDNA fragment encoding part of the extracellular domain and the entire transmembrane and cytoplasmic Twenty cases of neutropenia, not previously subjected to analysis of G-CSF-R mutations, were included in this study.
domains of the G-CSF-R. Alternatively, in cases in which RT-PCR with this set of primers gave low efficiencies of amplifiRelevant patient data are summarized in Table 1 . The diagnosis CN, SCN or Schwachmann-Diamond syndrome was cation primers FW3 and RV2 (spanning the entire cytoplasmic domain) were used. In one case in which RT-PCR products made on the basis of peripheral blood neutrophil counts, bone marrow examinations and clinical symptoms. [15] [16] [17] could not be obtained with either set of primers, PCR was performed on genomic DNA derived from bone marrow cells with primers FWI16 and RV2 ( Reverse transcriptase reaction and PCR amplification
Cloning Systems, La Jolla, CA, USA). Equal amounts of miniprep plasmid DNA from each clone were pooled and purified Total RNA and genomic DNA were extracted from bone marusing the Wizard Miniprep System (Promega Corporation, row mononuclear cells and circulating neutrophils using Madison, WI, USA). Double-stranded plasmid DNA was sequenced using the dideoxy chain-termination method with T7 polymerase (Pharmacia P-L Biochemicals, Milwaukee, WI, ucts, Rockland, ME, USA). Results mutation at nt 2396, whereas the mutation at nt 2390 was present in only a minor proportion of PCR products (Figure 2b ). Both mutations were confirmed by digestion with In two of the 20 cases included in this study, ie patients 8 and 9 (Table 1) , nucleotide changes in the G-CSF-R cytoplasmic MaeI and StuI of independent RT-PCR product and PCRamplified genomic DNA, ruling out PCR artefacts. Nucleotide domain were found. In the remaining cases, analysis on cDNA and/or genomic DNA did not reveal mutations or polymorsequencing DNA from single clones of PCR products showed that the mutations segregated, indicating that they were phisms.
Patient 8 is a 13-year-old boy. The diagnosis SCN was made present on different alleles of the G-CSF-R gene (data not shown). The mutations were not found in EBV-transformed B during the first year of life. G-CSF therapy started at the age of 6 years and continued for 6 years, until circulating blast cells of this patient (data not shown). cells were discovered. Subsequent analysis of bone marrow smears was indicative of AML (FAB-M4). Cytogenetic analysis showed 46, XY (20%)/46, XY, der(9) t(6;9)(q15;q34) (80%). Discussion The mutation in this patient is a C→T transition at nucleotide (nt) position 2390 of the G-CSF-R cDNA (Figure 1a ). This Previously, we identified three SCN patients with nonsense mutations in the G-CSF-R gene. These point mutations mutation creates a stop at Gln 718, resulting in the truncation of 96 C-terminal amino acids of the receptor. The mutation resulted in the truncation of the C-terminal region of G-CSF-R, a region crucial for maturation induction by G-CSF. 22, 23 The was confirmed by StuI digestion of independent RT-PCR products from bone marrow cells using primer FW4 (with one truncated receptor proteins interfered with the maturation signaling function of wild-type G-CSF-R in a dominant negative mismatch to create a StuI restriction site in combination with the mutation 24 ) and primer RV6 ( Figure 1b , Table 2 ). The tranfashion. 24 Because two of the SCN patients with G-CSF-R mutations developed AML, and because the mutations were script from the normal G-CSF-R allele was present at approximately equimolar levels (Figure 1b) .
exclusively present in a clonally expanded myeloid cell population in the neutropenic phase of the disease, it was thought Patient 9 is a 17-year-old boy with a primary diagnosis SCN. G-CSF therapy started at the age of 12 years. At that time that mutations disrupting the maturation signaling function of G-CSF-R could be associated with progression to leukemia. and on reexamination after 4 years on G-CSF, chromosome anlaysis of bone marrow cells showed no abnormalities. After
In the present study, we have examined 20 additional cases with various types of congenital neutropenia for the presence 5 years, del(6q) and monosomy 7 were detected in the bone marrow. The patient remained clinically well on G-CSF therof G-CSF-R mutations. This group of patients included inherited and noninherited forms, as well as two patients with apy, until he developed AML 9 months later. The bone marrow cells of this patient, collected before he developed overt disease progression to AML. In these latter cases, we found nonsense mutations in the G-CSF-R gene truncating the C-AML, contained two G-CSF-R mutations. Both were C→T transitions, at nt 2390 and nt 2396, respectively (Figure 2a) .
terminal maturation domain. Thus a total of five SCN cases with such mutations have been identified thus far (Figure 3) . The mutation at nt 2390 is identical to the one of patient 8 and creates a stop at Gln 718 (Figure 3) . The mutation at nt None of these patients had a family history of neutropenia. Initially, they responded well to G-CSF therapy and required 2396 creates a stop at Gln 720 ( after variable intervals of G-CSF therapy, ie 0.7, 2, 5.7 and the mutations were present in a major and a minor cell population, respectively. Based on the intensity of the band rep-6 years, of G-CSF therapy. The fifth patient remains in the neutropenic phase and continues on G-CSF therapy for more resenting the wild-type sequence in Figure 2 , we assume that the major cell clone contains a mutated (at nt 2396) and a than 6 years. Strikingly, two mutations were found in the myeloid cells of wild-type allele. This would be consistent with the clinical observation that patient 9 responded equally well to G-CSF patient 9. The mutations segregated in cloned PCR products, indicating that they were not present on the same allele. The therapy as the patients with a single G-CSF-R mutation. The minor clone (with the mutation at 2390) may have emerged yield of PCR product with C→T at nt 2396 was much greater than that with C→T at nt 2390 (Figure 2b ). This suggests that independently from the major clone and contain one mutated and one normal allele. Alternatively, the minor clone may Acknowledgements have been derived from the major clone and express both mutations.
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The present study and earlier reports 28, 29 suggest that the G- 
